reports
Insight Enterprises, Inc. Announces Pricing of $500 Million Offering o...
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it has priced $500 million aggregate principal amount of 6.625% senior notes due 2032 (the “notes”). The Company expects to use the net proceeds of the offering to repay a portion of the outstanding borrowings under its senior secured revolving credit facility due 2027 and, to the extent of any remaining net proceeds, for general corporate purposes. The sale of the notes is expected to close on May 20, 2024, subject to customary closing conditions. The notes will be senior unsecur...
Moody's Ratings assigns Ba2 CFR to Insight Enterprises and Ba3 to prop...
Moody's Ratings (Moody's) assigned a Ba2 Corporate Family Rating (CFR) and Ba2-PD Probability of Default Rating to Insight Enterprises, Inc. (Insight Enterprises). Moody's also assigned a Ba3 to the proposed senior unsecured notes and a SGL-2 Speculative Grade Liquidity (SGL) rating. Net proceeds fr...
Insight Enterprises, Inc. Announces Proposed $500 Million Offering of ...
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Senior Notes due 2032 (the “notes”). The Company expects to use the net proceeds of the offering to repay a portion of the outstanding borrowings under its senior secured revolving credit facility due 2027 and, to the extent of any remaining net proceeds, for general corporate purposes. The notes will be senior unsecured obligations of the Company and will be guaranteed on a sen...
- Jonathan Moreland
CNMD CONMED CORPORATION
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
ZOM ZOMEDICA PHARMACEUTICALS CORP
EYE NATIONAL VISION HOLDINGS
CDLX CARDLYTICS INC
ISDR ISSUER DIRECT CORP.
FSK FS KKR CAPITAL CORP
GO GROCERY OUTLET HOLDING
FNWB FIRST NORTHWEST BANCORP
FOUR SHIFT4 PAYMENTS
HQL INC.
TLS TEKLA LIFE SCIENCES INVESTORS
TMCI TELOS
FLYW TREACE MED CONCEPTS INC
BGS FLYWIRE CORP
DCGO B&G FOODS
BHVN INC.
GRNT DOCGO INC
VSTS_w BIOHAVEN LTD
BHRB GRANITE RIDGE RESOURCES INC
VESTIS CORPORATION
BURKE HERBERT FINANCIAL SERVICES CORP
Insight to Present at J.P. Morgan 52nd Annual Global Technology, Media...
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”) today announced that it is scheduled to participate in the following upcoming investor conference: J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference Tuesday, May 21, 2024, 8:10 AM ET Participants: Glynis Bryan, CFO The Insight presentation will be broadcast live over the Internet at where you can also view other recent webcasts, downloadable slide presentations and other investor information. About Insight Insight Enterprises, Inc. is a global Fortune 500 Solutions ...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phas...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medi...
Insight Enterprises, Inc. Announces Investor Meetings for Potential Of...
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”) announced today that it intends to hold one or more meetings with potential investors with respect to a potential offering of senior notes (the “notes”) in a transaction exempt from the registration requirements under the Securities Act of 1933 (the "Offering"), the proceeds of which are expected to be used to repay a portion of the outstanding borrowings under its senior secured revolving credit facility due 2027 and, to the extent of any remaining net proceeds, for general corporate purposes. There ca...
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent ...
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first quarter 2024. Recent Business Highlights CUE-101 abstract accepted for an oral presentation and poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 31-June 4, 2024.C...
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the , the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually. Presentation Details Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDTSession: Po...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Qua...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, ...
Kymera Therapeutics to Participate in Upcoming May Investor Conference...
Kymera Therapeutics to Participate in Upcoming May Investor Conferences WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; andTD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m. ET. Live webcasts of the presentations...
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life...
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024. During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress. Presentation Details The Citizens J...
Old Republic International Corp: 2 directors
Two Directors at Old Republic International Corp bought/maiden bought 6,528 shares at between 29.770USD and 30.240USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
ORI OLD REPUBLIC INTERNATIONAL CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
CVS CVS HEALTH CORPORATION
SWKS SKYWORKS SOLUTIONS INC.
CECE CECO ENVIRONMENTAL CORP.
CPZ CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
TBBK THE BANCORP
CFFI INC.
C&F FINANCIAL CORPORATION
Insight Enterprises, Inc. Reports Record First Quarter Results
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) today reported financial results for the quarter ended March 31, 2024. Highlights include: Gross profit increased 13% year over year to a record $440.9 million with gross margin expanding 170 basis points to a first quarter record 18.5% Insight Core services gross profit grew 24% year over year Cloud gross profit grew 33% year over year First quarter record results: Earnings from operations increased 29% year over year to $100.0 million Adjusted earnings from operations increased 30% ...
CFO of Insight, Glynis Bryan, Announces Retirement
CHANDLER, Ariz.--(BUSINESS WIRE)-- Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”), announced today that Glynis Bryan plans to retire as Chief Financial Officer effective December 31, 2024. Ms. Bryan, 65, has been with the Company since December 17, 2007. Ms. Bryan will continue to serve as the Chief Financial Officer through the end of the year. She will then transition to an advisory role. The Company has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Ms. Bryan will assist the Company in the search process. M...
Appian Announces First Quarter 2024 Financial Results
Appian Announces First Quarter 2024 Financial Results First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights: Revenue: Cloud subscription ...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into ...
Insight Acquires Infocenter, 2024 ServiceNow Partner of the Year
CHANDLER, Ariz.--(BUSINESS WIRE)-- (NASDAQ: NSIT) announced it has , a fast-growing pure-play ServiceNow Elite Partner, adding a full complement of ServiceNow consulting, implementation and managed services to its automation solutions portfolio. Client demand for intelligent enterprise automation continues to grow rapidly, fueling a market that’s estimated at $220 billion by 2025. , the 2024 ServiceNow Americas Consulting and Implementation Partner of the Year, works with clients around the world to implement ServiceNow capabilities and pursue aggressive digital transformation goals. “Wor...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.